Country: Canada
Language: English
Source: Health Canada
TACROLIMUS (TACROLIMUS MONOHYDRATE)
SANDOZ CANADA INCORPORATED
L04AD02
TACROLIMUS
1MG
CAPSULE (IMMEDIATE RELEASE)
TACROLIMUS (TACROLIMUS MONOHYDRATE) 1MG
ORAL
100
Prescription
IMMUNOSUPPRESSIVE AGENTS
Active ingredient group (AIG) number: 0127857002; AHFS:
APPROVED
2013-11-22
_Sandoz Tacrolimus (tacrolimus) _ _Page 1 of 89_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR SANDOZ ® TACROLIMUS Tacrolimus tacrolimus immediate release capsules 0.5 mg, 1 mg and 5 mg, for oral use USP IMMUNOSUPPRESSANT Sandoz Canada Inc. 110 rue de Lauzon Boucherville, QC J4B 1E6 Date of Initial Authorization: June 11, 2014 Date of Revision: April 12, 2023 Submission Control Number: 272173 _Sandoz Tacrolimus (tacrolimus) _ _Page 2 of 89_ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Hematologic 01/2023 7 WARNINGS AND PRECAUTIONS, Immune 01/2023 7 WARNINGS AND PRECAUTIONS, Renal 01/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS .......................................................................................................... 4 1.1 Pediatrics .......................................................................................................................... 5 1.2 Geriatrics .......................................................................................................................... 5 2 CONTRAINDICATIONS............................................................................................. 5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ........................................................ 6 4 DOSAGE AND ADMINISTRATION ............................................................................ 6 4.1 Dosing Considerations ...................................................................................................... 6 4.2 Recommended Dose and Dosage Adjustment .................................................... Read the complete document